Sexually Transmitted Diseases, Viral
Welcome,         Profile    Billing    Logout  
 124 Companies   161 Products   161 Products   116 Mechanisms of Action   11 Trials   2428 News 


«12345678910111213...4950»
  • ||||||||||  Trial completion:  HIV Risk Reduction in Youth in the Bahamas (clinicaltrials.gov) -  Nov 7, 2017   
    P=N/A,  N=1360, Completed, 
    Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change:  ANRS CO16: Cohort of HIV Associated Lymphomas (clinicaltrials.gov) -  Nov 6, 2017   
    P=N/A,  N=205, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | N=400 --> 205
  • ||||||||||  Enrollment change, Trial termination:  Pilot Study of Diflunisal in HIV-infected Adults (clinicaltrials.gov) -  Oct 27, 2017   
    P4,  N=8, Terminated, 
    Active, not recruiting --> Completed | N=400 --> 205 N=20 --> 8 | Suspended --> Terminated; Insufficient enrollment.
  • ||||||||||  Enrollment closed, Trial primary completion date:  TLCIDU Kenya: Testing and Linkage to Care for Injecting Drug Users in Kenya (clinicaltrials.gov) -  Oct 20, 2017   
    P=N/A,  N=8800, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  Enrollment closed, Trial initiation date, Trial primary completion date, IO biomarker:  MicroVIH: Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection (clinicaltrials.gov) -  Oct 6, 2017   
    P1/2,  N=45, Active, not recruiting, 
    Active, not recruiting --> Completed Completed --> Active, not recruiting | Initiation date: Jun 2011 --> Jan 2017 | Trial primary completion date: Aug 2013 --> Jun 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS (clinicaltrials.gov) -  Oct 5, 2017   
    P=N/A,  N=82, Completed, 
    Completed --> Active, not recruiting | Initiation date: Jun 2011 --> Jan 2017 | Trial primary completion date: Aug 2013 --> Jun 2018 Recruiting --> Completed
  • ||||||||||  Phase classification, Enrollment change, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  The Effect of Probiotics in HIV-1 Infection (clinicaltrials.gov) -  Sep 28, 2017   
    P=N/A,  N=32, Completed, 
    Recruiting --> Completed Phase classification: P2 --> P=N/A | N=100 --> 32 | Trial primary completion date: Jun 2012 --> Apr 2013
  • ||||||||||  Eyevinal (ibudilast) / MediciNova
    Enrollment closed, Trial primary completion date:  IBUD ph II: Trial of Ibudilast for Methamphetamine Dependence (clinicaltrials.gov) -  Sep 25, 2017   
    P2,  N=140, Active, not recruiting, 
    Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017
  • ||||||||||  metformin / Generic mfg.
    Trial suspension:  Improving Fibrosis Outcomes With Metformin (clinicaltrials.gov) -  Sep 25, 2017   
    P2,  N=60, Suspended, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Dec 2017 Not yet recruiting --> Suspended
  • ||||||||||  Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
    Trial completion:  Safety and Efficacy of E/C/F/TAF (Genvoya (clinicaltrials.gov) -  Sep 20, 2017   
    P2,  N=279, Completed, 
    Not yet recruiting --> Suspended Active, not recruiting --> Completed
  • ||||||||||  carboplatin / Generic mfg., pemetrexed / Generic mfg.
    Trial completion, Metastases:  CHIVA: Chemotherapy for Lung Cancer in HIV-positive Patients (clinicaltrials.gov) -  Sep 20, 2017   
    P2,  N=62, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Chronic HIV Infection and Aging in NeuroAIDS (CHAIN) (clinicaltrials.gov) -  Sep 11, 2017   
    P=N/A,  N=21, Completed, 
    Phase classification: P4 --> P=N/A Recruiting --> Completed | N=40 --> 21 | Trial primary completion date: Feb 2011 --> Dec 2014
  • ||||||||||  Rukobia (fostemsavir) / ViiV Healthcare
    Trial completion, Trial primary completion date:  HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections (clinicaltrials.gov) -  Sep 7, 2017   
    P2b,  N=246, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> May 2017
  • ||||||||||  Phase classification:  Metabolic Effects of Non-Thymidine Analogue Anti-HIV Medications (clinicaltrials.gov) -  Sep 5, 2017   
    P=N/A,  N=56, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Feb 2013 --> May 2017 Phase classification: P2 --> P=N/A
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Effectiveness of Antiretroviral Therapy During Acute HIV Infection (clinicaltrials.gov) -  Aug 31, 2017   
    P1,  N=25, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | N=36 --> 25 | Trial primary completion date: Jun 2014 --> Feb 2013
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies (clinicaltrials.gov) -  Aug 28, 2017   
    P=N/A,  N=24, Completed, 
    Active, not recruiting --> Completed | N=36 --> 25 | Trial primary completion date: Jun 2014 --> Feb 2013 Active, not recruiting --> Completed | N=30 --> 24 | Trial primary completion date: Aug 2008 --> Mar 2009
  • ||||||||||  Isentress (raltegravir) / Merck (MSD)
    Trial completion, Enrollment change, Trial primary completion date:  Transplantation and the Use of Raltegravir in HIV-Infected Patients (clinicaltrials.gov) -  Aug 16, 2017   
    P=N/A,  N=17, Completed, 
    Recruiting --> Completed Recruiting --> Completed | N=10 --> 17 | Trial primary completion date: Oct 2017 --> Jun 2017
  • ||||||||||  Trogarzo (ibalizumab IV) / Theratechnologies, TaiMed Biologics
    Trial completion, Trial primary completion date:  Investigator-Sponsored Protocol - Continued Use of Ibalizumab (clinicaltrials.gov) -  Aug 16, 2017   
    P2,  N=5, Completed, 
    Recruiting --> Completed | N=10 --> 17 | Trial primary completion date: Oct 2017 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Dec 2016
  • ||||||||||  Trial completion, Trial primary completion date, IO biomarker:  Auto-HTAP: Auto-immunity and Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Aug 14, 2017   
    P=N/A,  N=629, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2017 --> Dec 2016 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jul 2014
  • ||||||||||  Biomarker, Trial completion, Enrollment change, Trial primary completion date:  Impact of Antiretroviral Therapy on Cardiac Biomarkers (clinicaltrials.gov) -  Jul 11, 2017   
    P=N/A,  N=40, Completed, 
    Trial primary completion date: Dec 2020 --> Nov 2017 Recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Jan 2010 --> Oct 2014
  • ||||||||||  VRC-HIVDNA016-00-VP / National Institute of Allergy and Infectious Diseases
    Trial completion, Viral vector:  "Prime-Boost" Vaccine Schedule for Prevention of HIV Infection (clinicaltrials.gov) -  Jun 30, 2017   
    P1,  N=40, Completed, 
    Recruiting --> Completed | N=20 --> 40 | Trial primary completion date: Jan 2010 --> Oct 2014 Active, not recruiting --> Completed